Stay informed with the latest litigation news. Explore now

IP Verse

Amgen Research Munich competitive analysis

Latest publications and patents of Amgen Research Munich New

Explore the latest publications and patents granted to Amgen Research Munich, showcasing their recent innovations and technological advancements.

Last updated on: Sep 6, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Amgen Research Munich

EP3819007
Jul 10, 2024Dosing Regimen For Anti-Bcma AgentsGranted And Under Opposition
EP4058148
Mar 13, 2024Dosing Regimen For Anti-Bcma AgentsGranted And Under Opposition
EP2637670
Mar 13, 2024Prevention Of Adverse Effects Caused By Cd3 Specific Binding DomainsPatent Maintained As Amended
EP3531133
Aug 23, 2023Risk-Stratification Of B-Precursor Acute Lymphoblastic Leukemia PatientsRevoked
EP3411402
Dec 22, 2021Bcma And Cd3 Bispecific T Cell Engaging Antibody ConstructsGranted And Under Opposition
EP3228315
Nov 25, 2020Prevention Of Adverse Effects Caused By Cd3 Specific Binding DomainsGranted And Under Opposition
EP3412687
Mar 18, 2020Methods For Treating DlbclRevoked
EP2780375
Sep 11, 2019Binding Molecules For Bcma And Cd3Revoked
EP2780374
Aug 21, 2019Binding Molecules For Bcma And Cd3Revoked
EP3149480
Dec 26, 2018Risk-Stratification Of B-Precursor Acute Lymphoblastic Leukemia PatientsRevoked

Latest patents of Amgen Research Munich opposed by its competitors

Explore Amgen Research Munich's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 11, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3819007
Jul 10, 2024Dosing Regimen For Anti-Bcma Agents2
EP2637670
Mar 13, 2024Prevention Of Adverse Effects Caused By Cd3 Specific Binding Domains2
EP4058148
Mar 13, 2024Dosing Regimen For Anti-Bcma Agents3
EP3531133
Aug 23, 2023Risk-Stratification Of B-Precursor Acute Lymphoblastic Leukemia Patients1
EP3411402
Dec 22, 2021Bcma And Cd3 Bispecific T Cell Engaging Antibody Constructs1
EP3228315
Nov 25, 2020Prevention Of Adverse Effects Caused By Cd3 Specific Binding Domains2
EP3412687
Mar 18, 2020Methods For Treating Dlbcl1
EP2780375
Sep 11, 2019Binding Molecules For Bcma And Cd38
EP2780374
Aug 21, 2019Binding Molecules For Bcma And Cd37
EP3149480
Dec 26, 2018Risk-Stratification Of B-Precursor Acute Lymphoblastic Leukemia Patients1

Latest PTAB cases involving Amgen Research Munich New

Discover the latest PTAB cases involving Amgen Research Munich, highlighting their recent legal challenges and patent disputes.